Invivyd Q1 net loss per share misses on higher R&D costs

Invivyd

14/05/2026 12:11

Overview

U.S. biopharma firm's Q1 net product revenue grew 22% yr/yr

Q1 net loss per share missed analyst expectations

Outlook

Company anticipates DECLARATION pivotal trial top-line data for VYD2311 in Q3 2026

Invivyd says cash and cash equivalents expected to provide runway through DECLARATION data readout and support potential VYD2311 launch

Result Drivers

PEMGARDA REVENUE GROWTH - Co said Q1 revenue increase was driven by continued commercial execution of PEMGARDA even as vaccine uptake waned

R&D SPENDING - Higher operating expenses attributed to increased contract research costs for DECLARATION pivotal clinical trial for VYD2311

Company press release: ID:nGNX5lz6Mg

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
$13.74 mln
Q1 EPS
Miss
-$0.13
-$0.07 (3 Analysts)
Q1 Net Income
Miss
-$41.40 mln
-$16.13 mln (2 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Invivyd Inc is $10.00, about 580.3% above its May 13 closing price of $1.47

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)